503045364 11/03/2014

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT3091963

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
ELAN PHARMACEUTICALS, INC.	07/24/2013

RECEIVING PARTY DATA

Name:	BIOGEN IDEC INTERNATIONAL HOLDING LTD.
Street Address:	22 VICTORIA STREET
Internal Address:	CANON'S COURT
City:	HAMILTON
State/Country:	BERMUDA
Postal Code:	HM EX

PROPERTY NUMBERS Total: 1

Property Type	Number	
Patent Number:	7435802	

CORRESPONDENCE DATA

Fax Number: (650)798-2999

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 650.798.2962

Email: kathleen.farrell@aporter.com
Correspondent Name: ARNOLD & PORTER LLP
Address Line 1: 1801 PAGE MILL ROAD

Address Line 2: SUITE 110

Address Line 4: PALO ALTO, CALIFORNIA 94304

ATTORNEY DOCKET NUMBER:	BGN-0008 US C1
NAME OF SUBMITTER:	YUKO SONEOKA
SIGNATURE:	/YUKO SONEOKA/
DATE SIGNED:	11/03/2014

Total Attachments: 25

source=Final Executed EPI to BIIH Assignment_(WEST_33945943_1)#page1.tif source=Final Executed EPI to BIIH Assignment_(WEST_33945943_1)#page2.tif source=Final Executed EPI to BIIH Assignment_(WEST_33945943_1)#page3.tif source=Final Executed EPI to BIIH Assignment_(WEST_33945943_1)#page4.tif source=Final Executed EPI to BIIH Assignment_(WEST_33945943_1)#page5.tif

503045364 REEL: 034091 FRAME: 0048

PATENT

source=Final Executed EPI to BIIH Assignment_(WEST_33945943_1)#page6.tif
source=Final Executed EPI to BIIH Assignment_(WEST_33945943_1)#page7.tif
source=Final Executed EPI to BIIH Assignment_(WEST_33945943_1)#page8.tif
source=Final Executed EPI to BIIH Assignment_(WEST_33945943_1)#page9.tif
source=Final Executed EPI to BIIH Assignment_(WEST_33945943_1)#page10.tif
source=Final Executed EPI to BIIH Assignment_(WEST_33945943_1)#page11.tif
source=Final Executed EPI to BIIH Assignment_(WEST_33945943_1)#page12.tif
source=Final Executed EPI to BIIH Assignment_(WEST_33945943_1)#page13.tif
source=Final Executed EPI to BIIH Assignment_(WEST_33945943_1)#page14.tif
source=Final Executed EPI to BIIH Assignment_(WEST_33945943_1)#page15.tif
source=Final Executed EPI to BIIH Assignment_(WEST_33945943_1)#page16.tif
source=Final Executed EPI to BIIH Assignment_(WEST_33945943_1)#page17.tif
source=Final Executed EPI to BIIH Assignment_(WEST_33945943_1)#page18.tif
source=Final Executed EPI to BIIH Assignment_(WEST_33945943_1)#page19.tif
source=Final Executed EPI to BIIH Assignment_(WEST_33945943_1)#page20.tif
source=Final Executed EPI to BIIH Assignment_(WEST_33945943_1)#page21.tif
source=Final Executed EPI to BIIH Assignment_(WEST_33945943_1)#page22.tif
source=Final Executed EPI to BIIH Assignment_(WEST_33945943_1)#page23.tif
source=Final Executed EPI to BIIH Assignment_(WEST_33945943_1)#page24.tif
source=Final Executed EPI to BIIH Assignment_(WEST_33945943_1)#page25.tif

CWT 5/13/2013

PATENT ASSIGNMENT

For valuable consideration as set forth in that certain Asset Purchase Agreement dated as of February 5, 2013 (the "Asset Purchase Agreement") between Elan Pharmaceuticals, Inc., a Delaware corporation, having a place of business at 300 Technology Square, Third Floor, Cambridge, MA 02139, (the "Assignor") and Biogen Idea International Holding Ltd., a corporation of Bermuda having a place of business at:

Canon's Court 22 Victoria Street Hamilton HM EX Bermuda

and its successors and assigns (collectively hereinafter called the "<u>Assignee</u>"), Assignor hereby assigns to Assignee its entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, throughout the world in the inventions and improvements which are the subject of:

- a) Each of the patents and patent applications that are described in detail in <u>Schedule A</u>, annexed hereto and made a part hereof;
- b) Any and all applications that claim the benefit of the patents and patent applications described in detail in <u>Schedule A</u>, including any and all United States and foreign utility patents and patent applications, including non-provisional, continuing (continuation, continuation-in-part or divisional), reissue, and reexamination applications, utility models, and design registrations;
- c) Any and all inventions described in each of the patents and patent applications that are described in detail on Schedule A, and in all forms of intellectual and industrial property protection derivable therefrom, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patents and patent applications, including without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor, and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other

Assignment Page 1 of 3

- international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;
- d) All such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The Assignor agrees to execute all papers necessary to perfect the recordation of this Assignment in connection with the applications and Letters Patent as above, and any non-provisional, continuing (continuation, divisional or continuation-in-part), reissue, reexamination or corresponding applications thereof and also to execute separate assignments in connection with such applications as the Assignee may deem necessary or expedient to perfect the recordation of this Assignment.

The Assignor agrees to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the applications or Letters Patent or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application thereof and to cooperate with the Assignee at Assignee's expense in every reasonable way possible in obtaining evidence and going forward with such interference or patent enforcement act.

The Assignor agrees to perform all affirmative acts at Assignee's request and expense that may be necessary to obtain or ensure a grant of a valid patent to the Assignee.

The Assignor hereby represents that Assignor has full right and authority to convey the entire interest herein assigned, and that Assignor has not executed, and will not execute, any agreement in conflict therewith.

The Assignor hereby grants the current patent practitioner(s) for each patent application or patent in the attached <u>Schedule A</u> the power to insert in this assignment, including the attached <u>Schedule A</u>, any further information regarding the patents and patent application so identified in <u>Schedule A</u> that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

Notwithstanding any other provision of this Assignment to the contrary, nothing contained in this Assignment shall in any way supersede, modify, replace, amend, change, rescind, waive, exceed, expand, enlarge or in any way affect the provisions set forth in the Asset Purchase

Assignment Page 2 of 3

Agreement nor shall this Assignment reduce, expand or enlarge any remedies under the Asset Purchase Agreement including, without limitation, any representations or warranties specified therein. In the event of any conflict or inconsistency between this Assignment and the Asset Purchase Agreement, the terms of the Asset Purchase Agreement shall prevail.


This Assignment shall be binding upon and inure to the benefit of Assignor, Assignee and their respective successors and permitted assigns.

[Signature pages follow.]

Assignment Page 3 of 3

ELAN PHARMACEUTICALS, INC.

By:	CORPL.
Name:	Caterina M. Lunb
Title:	and IP Officer
Date:	7/24/2013
Before me this 24 day of day of appeared whenown to me to be the	person whose name is subscribed to the foregoing
Assignment, proved to me through satisfactor	
his/her free act and deed for the purposes the	
	Aaron Moll
	otary Public
M	y Commission Expires: $5/26/26/9$



[Notary's Seal Here]

[SIGNATURE PAGE TO PATENT ASSIGNMENT]

32994892_4

	BIOGEN I	DEC INTERNATIO	NAL HOLDING LTD.
	Ву:	Duiss	
	Name:	1. TONESAN A	YISSAH
		DIRECTOR	
	Date:	JUL 2 3 2013	
Before me this <u>25</u> appeared <u>A. TONE JAM</u> known to me	lay of	JULY erson whose name is	, 20, personally subscribed to the foregoing
Assignment, proved to me through s			
PASSPORT	, and ack	nowledged that he/sl	he executed the same as
_his/her free act and deed for the purp			
	<u> </u>	Whe	
	$\setminus I$	ry Public	
	My	Commission Expires:	nfa
⊌ Here]			
		Jennifer S. Eve	
		Notary Public	
		Canon's Court 22 Victoria Street	****
		P.O. Box HM 1179	***************************************
4 2 .		Hamilton HM EX Bermuda	observed to the second
		Inches 1111 2 3	<i>)</i>

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0002-AU	2011323820	Oct-24-2011		METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IS SVCAM AND/OR SMAGCAM LEVELS
EUN-0002-CA	2,816,016	Oct-24-2011		METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IS 5VCAM AND/OR #MAdCAM LEVELS
ELN-0002-EP	11838481.7	Oct-24-2011		METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IS SVCAM AND/OR SMAJCAM LEVELS
ELN-0002-JP	тво	Oct-24-2011		METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IS SVCAM AND/OR SMAdCAM LEVELS
ELN-0002-PR	61/406,358	Oct-25-2010		METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN SVCAM AND/OR MADCAM LEVELS
ELN-0002-PR1	61/406,365	Oct-25-2010		METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS
ELN-0002-US	13/881,520	Oct-24-2011		METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IS SVCAM AND/OR SMAdCAM LEVELS
ELN-0002-WO	PCT/US2011/057519	Oct-24-2011		METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IS sVCAM AND/OR sMAdCAM LEVELS

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0003-CA	2,641,513	Feb-28-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0003-EP	07751683.9	Feb-28-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0003-EP-D1	13175987.0	Feb-28-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0003-JP	2008-557327	Feb-28-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0003-US	11/711,628	Feb-28-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0003-US-D1	12/757,305	Apr-09-2010		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0003-WO	PCT/US2007/004943	Feb-28-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0004-AU	2007224228	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-BR	P1 6708392-0	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-CA	2,644,110	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-CN	200780015815.5	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-CO	08.105.676	Mar-92-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-DZ	080582	Mar-02-2007	6107	METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-EA	200801933	Mar-02-2007	016626	METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-EC	PCT-08-8788	Mar-02-2007	, , , , , , , , , , , , , , , , , , , ,	METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-EG	i 440/2008	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-EP	07751993,2	Mar-92-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-ID	W00200803172	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-IL	193775	Mar-02-2007	193775	METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-IN	8058/DELNP/2008	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-JP	2008-558307	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB

SCHEDULE A TO PATENT ASSIGNMENT PAGE 2 OF 20

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0004-JP-D1	2012-264135	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-KR	10-2008-7023464	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
EUN-0004-MA	PV/31249	Mar-02-2007	30287	METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-MX	MX/a/2008/011176	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-MY	PI 20083409	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-NZ	570852	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-NZ- D1-	596359	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-NZ-D2	610405	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-PH	1-2008-501982	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-RS	P-391/2008	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-SG	200806732-4	Mar-02-2007	146063	METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-SG-DI	201101499-0	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-US	11/713,000	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-US-CI	13/425,058	Mar-20-2012		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0604-WO	PCT/US2007/005265	Mar-02-2007		METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB
ELN-0004-ZA	2008/07346	Mar-02-2007	2008/07346	METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB

SCHEDULE A TO PATENT ASSIGNMENT PAGE 3 OF 20

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0007-CA	2,066,738	Sep-13-1990	2,066,738	BLOOD-BRAIN BARRIER MODEL
ELN-0007-JP	2-513049	Sep-13-1990	3308526	BLOOD-BRAIN BARRIER MODEL
ELN-0007-JP-D1	2001-398632	Sep-13-1990		BLOOD-BRAIN BARRIER MODEL
ELN-0007-US	07/413,274	Sep-27-1989		BLOOD-BRAIN BARRIER MODEL
ELN-0007-US-C1	08/402,962	Mar-10-1995		COMPOSITIONS AND METHODS FOR MODULATING LEUKOCYTE ADHESION TO BRAIN ENDOTHELIAL CELLS
ELN-0007-U8-C2	08/457,847	Jun-01-1995	6,033,665	COMPOSITIONS AND METHODS FOR MODULATING LEUKOCYTE ADHESION TO BRAIN ENDOTHELIAL CELLS
ELN-0007-US- CIPI	07/577,650	Sep-04-1990	5,260,210	BLOOD-BRAIN BARRIER MODEL
ELN-0007-US- CIP2	07/871,223	Apr-17-1992		COMPOSITIONS AND METHODS FOR MODULATING LEUKOCYTE ADHESION TO BRAIN ENDOTHELIAL CELLS

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0008-AT	95908741.2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-AU	16960/95	Jan-25-1995	703152	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-BE	95908741.2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-CA1	2,182,013	Jan-25-1995	2,182,013	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VI.A-4
ELN-0008-CA2	2,237,808	Nov-21-1996		THERAPEUTIC USES OF HUMANIZED ANTIBODIES AGAINST ALPHA-4 INTEGRIN
ELN-0008-CH	95908741.2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VI.A-4
ELN-0008-CN	95191354,9	Jan-25-1995	ZL95191354.9	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-DE	95908741.2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-DK	95908741.2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-EP1	95908741.2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-EP2	96943512.2	Nov-21-1996		THERAPEUTIC USES OF HUMANIZED ANTIBODIES AGAINST ALPHA-4 INTEGRIN

SCHEDULE A TO PATENT ASSIGNMENT PAGE 4 OF 20

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0008-EP-D1	06013916.9	Jan-25-1995	1759709	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-ES	95908741.2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-FI	962958	Jan-25-1995	117509	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-FR	95908741.2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-GB	95908741.2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-GR	95908741.2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-HU	P9602019	Jan-25-1995	220,799	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-IE	95908741.2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-IT	95908741.2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-JF:	7-519770	Jan-25-1995	4115517	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-JP2	9-519938	Nov-21-1996		THERAPEUTIC USES OF HUMANIZED ANTIBODIES AGAINST ALPHA-4 INTEGRIN
EL.N-0008-JP-D1	2005-228930	Jan-25-1995		HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VI.A-4
ELN-0008-JP-DIV	2008-153420	Nov-21-1996		THERAPEUTIC USES OF HUMANIZED ANTIBODIES AGAINST ALPHA-4 INTEGRIN
ELN-0008-JP-D2	2009-120421	Jan-25-1995		HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-JP-D3	2013-28635	Jan-25-1995		HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-JP-D4	2013-54628	Jan-25-1995		HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-KR	10-1996-0703987	Jan-25-1995	367948	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-LU	95908741.2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-MC	95908741,2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-MX	962971	Jan-25-1995	198845	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-NL	95908741.2	Jan-25-1995	9894237	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-NO	19963097	Jan-25-1995	319.867	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4

SCHEDULE A TO PATENT ASSIGNMENT PAGE 5 OF 20

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0008-NZ	279730	Jan-25-1995	279730	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-PL	P315634	Jan-25-1995	181827	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-PT	95908741.2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-SE	95908741.2	Jan-25-1995	0804237	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-US	08/186,269	Jan-25-1994		FIUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-US- CP1	08/561,521	Nov-21-1995	5,840,299	HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-0008-US02	09/155,739	Nev-21-1996		THERAPEUTIC USES OF HUMANIZED ANTIBODIES AGAINST ALPHA-4 INTEGRIN
ELN-0008-US-C1	11/006,808	Dec-08-2004	7,435,802	HUMANIZED ANTI-VLA4 IMMUNOGLOBINS
ELN-0008-US-C2	12/175,116	Jul-17-2008	8,246,958	METHODS OF INHIBITING ALPHA-4 DEPENDENT INTERACTIONS WITH VCAM-1 WITH ANTI-VLA-4 ANTIBODIES
ELN-0008-US-C3	13/540,462	Jul-02-2012		THERAPEUTIC USES OF HUMANIZED ANTIBODIES AGAINST ALPHA-4 INTEGRIN
ELN-0008-WO01	PCT/US1995/001219	Jan-25-1995		HUMANIZED ANTIBODIES AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4
ELN-9998-WO02	PCT/US1996/018807	Nov-21-1996		THERAPEUTIC USES OF HUMANIZED ANTIBODIES AGAINST ALPHA-4 INTEGRIN

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0009-AR	P030100608	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-AT	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009 AU	2003213231	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-AU-DI	2009201587	Feb-25-2003	2009201587	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-AU-D2	2012202155	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-BE	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-BG	03709277.2	Peb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION

SCHEDULE A TO PATENT ASSIGNMENT PAGE 6 of 20

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0009-BR	P10307975-9	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-CA	2,477,178	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INPLAMMATION
ELN-0009-CH	63709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-CL	357-2003	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-CN	03809138.0	Feb-25-2003	ZL03809138.0	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-CO	04095478	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-CY	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-CZ	03709277.2	Peb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-DE	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-DK	03709277.2	Peb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-EE	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-EG	191/2003	Feb-25-2003	•	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-EP	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-EP-D1	10012870.1	Feb-25-2003		ADMISSION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-EP-D2	10012871.9	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-EP-D3	10012872.7	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-ES	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-FI	03709277,2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION

SCHEDULE A TO PATENT ASSIGNMENT PAGE 7 OF 20

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0009-FR	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
EL.N-0009-GB	03709277,2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-GR	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-HK	05105001.1	Feb-25-2003	1073997	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-HK-D1	11113804.6	Feb-25-2003		ADMISSION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-HK-D2	12101864,7	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-HK-D3	11107644.2	Feb-25-2003		ADMISSION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-HU	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-ID	W-00200402079	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-IE	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-IL	163725	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-IL-D1	203515	Feb-25-2003		COMPOSITION COMPRISING A - 4 - INTEGRIN FOR TREATING INFLAMMATION
ELN-0009-IN	2103/CHENP/2004	Feb-25-2003	229010	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-IN-D1	2196/CHENP/2008	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-IT	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-JP	2003-570787	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-JP-D1	2011-015696	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-KR	10-2004-7013609	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-LU	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION

SCHEDULE A TO PATENT ASSIGNMENT PAGE 8 OF 20

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0009-MC	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-MX	PA/a/2004/008267	Feb-25-2003	310728	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-MY	P120030650	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-NL	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-NO	20044054	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-NZ	535320	Feb-25-2003	535320	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-NZ-D1	566530	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009 -NZ-D2	579583	Feb-25-2003	579583	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-NZ-D3	591635	Peb-25-2003	591635	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-PE	195-03	Peb-27-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-PH	1-2004-501449	Feb-25-2003	1-2004-501449	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-PH-D1	1-2011-502301	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-PK	0161/03	Feb-26-2003	138459	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-PL	P-372306	Feb-25-2003	P-372306	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-PR1	60/360,134	Feb-25-2002		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-PR2	60/374,501	Apr-23-2002		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-PT	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-RU	2004128454	Feb-25-2003	235967	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-SA	93 24 0276	Sep-02-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION

SCHEDULE A TO PATENT ASSIGNMENT PAGE 9 OF 20

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0009-SE	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-SG	200404939-1	Feb-25-2003	107209 [WO 03/072040]	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-81	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-SK	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-TH	080345	Feh-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-TR	03709277.2	Feb-25-2003	1485127	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-TW	092103902	Feb-25-2003	1346558	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-TW-DI	100112502	May-03-2011		PHARMACEUTICAL COMPOSITION FOR DETERMINING EFFICACY OF CHRONIC TREATMENT OF INFLAMATION
BLN-0009-UA	20040907793	Feb-25-2003	85537	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-US	10/372,111	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-US-D1	11/540,640	Oct-02-2006	7,807,157	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-US-D2	12/846,350	Jul-29-2010		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-UY	27688	Feb-27-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-VE	2003-000630	Apr-22-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-6009-VN	1-2004-00960	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-WO	PCT/US2003/005421	Feb-25-2003		ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION
ELN-0009-ZA	2004/7406	Feb-25-2003	2004/7406	ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION

·		***************			
4 6.39 1725	:	:		•	:
24 CX F F H &			NCO 5 15 005	rema . e	:
	· Application No.	: Annication liste	Registration No.	8 3 5 8 6	:
2226226	: - x a		404 2410 4010 10 1 101	1 1030	:
A STATE CREAT		<i>;</i>		: .	:

SCHEDULE A TO PATENT ASSIGNMENT PAGE 10 OF 20

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-001C-AR	P040100225	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-AU	2004207536	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-AU2	2004207535	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-AU-DI	2010212446	San-26-2004	2010212446	COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-AU2-D1	2010201472	Jan-26-2904		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-AU-D2	2011201262	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-CA1	2,514,117	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-CA2	2,514,125	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-CL	0116-2004	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-CN	200480008089.0	Jan-26-2004	ZL200480008089.0	COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-6016-CO	05-084.319	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS

SCHEDULE A TO PATENT ASSIGNMENT PAGE 11 OF 20

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0010-EG	PCT 399/2005	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-EP	04705270.9	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-EP-DI	11008463.9	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-GC	GCC/P/2004/3259	Feb-28-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-IL	169770	Jan-26-2004	169770	COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-IN	1994/CHENP/2005	Jan-26-2004	229369	COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-JP	2006-503001	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-JP2	2006-502997	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-JP-D1	2011-121017	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-KR	10-2005-7013695	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-KR-D1	10-2012-7024847	Jan-26-2004	1260497	COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS

SCHEDULE A TO PATENT ASSIGNMENT PAGE 12 OF 20

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0010-MX	PA/a/2005/007843	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-MX !	MX/A/2005/007823	Jan-26-2994		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-MX-D1	MX/a/2008/007693	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-001-MX-D2	MX/a/2008/008267	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-MX-D3	MX/s/2010/001362	Jan-26-2004 、		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-MY	PI 20040214	Feb-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-NO	20053920	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-PE	100			COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-PH	1-2005-501355	Jan-26-2004	1-2005-501355	COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-PH-D1	1-2008-502081	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-PH-D2	1-2011-501872	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS

SCHEDULE A TO PATENT ASSIGNMENT PAGE 13 OF 20

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0010-PK	0040/2004	Jan-24-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-PR1	60/442,171	Jan-24-2003		REVERSAL OF INFLAMMATORY RESPONSE BY INHIBITION OF ALPHA-4 INTEGRIN TO INHIBIT DEMYELINATION
ELN-0010-PR2	60/500,316	Sep-05-2003		REVERSAL OF INFLAMMATORY RESPONSE BY INHIBITION OF ALPHA-4 INTEGRIN TO INHIBIT DEMYELINATION AND REVERSE PARALYSIS
ELN-0010-RU	2005126728	Jan-26-2004	2412721	COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-SG	200504585-1	Jan-26-2004	P113988	COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-SK	5064-2005	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-TH	088245	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-TW	093101747	Jan-27-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-TW-D1	101146999	Jan-27-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-UA	200508278	Jan-26-2004	88604	COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-UR	28170	Jan-25-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-US1	10/763,424	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS

SCHEDULE A TO PATENT ASSIGNMENT PAGE 14 OF 20

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0010-US2	10/763,539	Jan-26-2004	7,576,101	COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-VE	2004-000085	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-VN	1-2005-01185	Ian-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-WO	PCT/US2004/002039	Jan-26-2004		COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS
ELN-0010-ZA	2005/05869	Jan-26-2004	2005/05869	COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0011-AR	P040100411	Feb-10-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-AU	2004210679	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-AUD1	2010202254	Feh-09-2004	2010202254	IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-AUD2	2012202845	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-CA	2,515,444	Feh-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-C1.	0224-2004	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-CN	200480009441.2	Feb-09-2004	ZL200480009441.2	IMMUNOGLOBULIN FORMULATION AND METHO OF PREPARATION THEREOF
ELN-0011-CN-D1	201210292453.7	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-CO	05091313	Feb-09-2004		MMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-EG	PCT 440/2005	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-EP	04709508.8	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF

SCHEDULE A TO PATENT ASSIGNMENT PAGE 15 OF 20

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0011-EP-DI	10005235,6	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-GC	GCC/P/2004/3212	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHO OF PREPARATION THEREOF
ELN-0011-HK	06111920.6	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-IL	170008	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHO OF PREPARATION THEREOF
ELN-0011-EN	2187/CHENP/2005	Feb-09-2004	252222	IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-JP	2006-503453	Feb-09-2004	4728948	IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-JP-D1	2010-277365	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-KR	10-2005-7014654	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-MX	PA/a/2005/008409	Feb-09-2004	302966	IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-MX-DI	MX/a/2012/010160	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-MY	PI 20040377	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-NO	20054164	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-PE	149/2004	Feb-10-2004	\$147	IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-PH	1-2005-501425	Feb-09-2004	1-2005-501425	IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-PK	0078/04	Feb-09-2004	138744	IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-PR	60/445,818	Feb-10-2003		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-PRI	60/929,133	Jun-14-2007		LYOPHILIZED IMMUNOGLOBULIN FORMULATION AND METHOS OF PREPARATION
ELN-0011-RU	2005128280	Feb-09-2004	2358763	IMMUNOGLOBULIN FORMULATION AND METHO OF PREPARATION THEREOF
ELN-0011-SG	200505045-5	Feb-09-2004	114176	IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-SK	PV 5067-2005	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-TH	088577	Feb-06-2004		IMMUNOGLOBULIN FORMULATION AND METHO OF PREPARATION THEREOF
ELN-0011-TW	093103043	Feb-10-2004	1367766	IMMUNOGLOBULIN FORMULATION AND METHID OF PREPARATION THEREOF

SCHEDULE A TO PATENT ASSIGNMENT PAGE 16 OF 20

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0011-UA	200508632	Feb-09-2004	82685	IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-US	10/773,406	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-US-C2	12/572,978	Oct-02-2009	8,349,321	IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-US2	13/605,590	Sep-06-2012		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-US3	13/676,866	Nov-14-2012		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-UY	28184	Feb-10-2003		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-VE	2004-000165	Feb-04-2004		IMMUNOGLOBULIN FORMULATION AND METHO OF PREPARATION THEREOF
ELN-0011-VN	1-2005-01248	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-WO	PCT/US2004/003873	Feb-09-2004		IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF
ELN-0011-ZA	2005/06159	Feb-09-2004	2005/06159	IMMUNOGLOBULIN FORMULATION AND METHD OF PREPARATION THEREOF

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0012-AR	P050100431	Feb-04-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-AU	2005213324	Feb-03-2005	2005213324	METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-AU-D1	2011211351	Feb-03-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-BR	PI0507451.7	Feb-03-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-CA	2,555,365	Feb-03-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-CL	203-2005	Feb-02-2005	45,773	METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-CN	200580012148.6	Feb-03-2005	ZL200580012148.6	METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-EA	200601433	Feb-03-2005	009873	METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-EP	05712339.0	Peb-03-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-EP-D1	11005763.5	Peb-03-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-GC	GCC/P/2005/4271	Peb-06-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE

SCHEDULE A TO PATENT ASSIGNMENT PAGE 17 OF 20

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0012-HK	07104930.8	Feb-03-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-ID	W-00200602188	Feb-03-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-IL	177201	Feb-03-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-IN	3236/CHENP/2006	Feb-03-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-JP	2006-552178	Feb-03-2005	4996261	METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-KR	10-2006-7018079	Peb-03-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-MX	PA/a/2006/008746	Feb-03-2005	286237	METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-MY	Pt 20050455	Feb-04-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-NO	2006 3951	Feb-03-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-NZ	548851	Feb-03-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-NZ-D1	584288	Feb-03-2005	584288	METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-NZ-D2	595379	Feb-03-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-PE	129,2005	Feb-04-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-PH	1-2006-501514	Feb-03-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-PK	0068/05	Feb-02-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-PR	60/541,946	Feb-06-2004		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-TH	097446	Feb-15-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-TW	094103833	Feb-05-2005	1375563	METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-US	11/049,365	Feb-03-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-UY	28741	Feb-04-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-VE	2005-000205	Feb-04-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
ELN-0012-WO	PCT/US2005/002860	Feb-03-2005		METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE

SCHEDULE A TO PATENT ASSIGNMENT PAGE 18 OF 20

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0012-ZA	2006/06557	Feb-03-2005	2006/06557	METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0013 AU	2005232571	Mar-30-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-AU 2	2005231467	Apr-01-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-AU-D1	2011213878	Mar-30-2005	2011213878	STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-CA 2	2,561,164	Apr-01-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-CA	2,561,364	Mar-30-2005	•••••••••••••••••••••••••••••••••••••••	STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-CL	742-2005	Mar-31-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-EP	05768245.2	Mar-30-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013 EP2	05763852.0	Apr-01-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-GC	GCC/P/2005/4496	Apr-02-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-HK	07106887.6	Mar-30-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013 HK2	07110080,3	Mar-30-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-IL	178302	Mar-30-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-JP	2007-506536	Mar-30-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-JP 2	2007-506344	Apr-01-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-JP-D1	2013-080823	Mar-30-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-MY	PI 20051380	Mar-29-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-NO	2006 4979	Mar-30-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-NZ	550040	Mar-30-2005	•••••••••••••••••••••••••••••••••••••••	STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-NZ-D1	580057	Mar-30-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-NZ-D2	594476	Mar-30-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-PR	60/558,120	Apr-01-2004		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-PR1	60/558,121	Apr-01-2004		STEROID SPARING AGENTS AND METHODS OF USING SAME
ELN-0013-TH	099245	Mar-30-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-TW	094110385	Mar-31-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-US1	11/095,822	Apr-01-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-US2	11/096,074	Apr-01-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-UY	28838	Apr-01-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME
ELN-0013-WO	PCT/US2005/010848	Mar-30-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME

SCHEDULE A TO PATENT ASSIGNMENT PAGE 19 OF 20

A&P File Reference	Application No.	Application Date	Registration No.	Title
ELN-0013 WO2	PCT/US2005/011307	Apr-01-2005		STEROID SPARING AGENTS AND METHODS OF USING THE SAME

SCHEDULE A TO PATENT ASSIGNMENT PAGE 20 OF 20

PATENT REEL: 034091 FRAME: 0074

RECORDED: 11/03/2014